GDF15 and obstructive sleep apnea syndrome: Consequently, GDF15 may improve the estimation of the pretest probability of arteriosclerosis and present new targets for diagnosing and treating OSA-associated arteriosclerosis, further reducing CVD morbidity and mortality in individuals with OSA.